Read by QxMD icon Read


Jung-Jyh Hung, Shiu-Feng Huang, Ying-Ying Shen, Yu-Chung Wu, Teh-Ying Chou, Wen-Hu Hsu
BACKGROUND: The programmed cell death-ligand 1 (PD-L1) pathway plays an important role in maintaining immune homeostasis. The PD-L1 pathway may also protect tumors from attack by cytotoxic T cells. Blockade of programmed cell death 1 (PD1) or PD-L1 induced durable tumor regression in patients with advanced cancers, including non-small cell lung cancer (NSCLC). However, the prognostic value of PD-L1 expression in patients with lung adenocarcinoma remains controversial. METHODS: A total of 112 patients with resected lung adenocarcinoma were included in the study...
October 12, 2016: Annals of Thoracic Surgery
Umberto Maggiore, Julio Pascual
Cancer immunotherapy, especially the use of checkpoint inhibitors, is expanding and can be efficacious in organ transplant recipients with malignant neoplasia. In this review, we summarize clinical findings and evolution of several patients treated with CTL4-4 or PD-1 inhibitors reported in the literature. The CTL-4 inhibitor ipilimumab has been safely used in several liver and kidney allograft recipients. PD1-inhibitors look promising for tumor shrinking, but acute rejection is the rule, so they should be avoided in recipients of life-saving organs...
September 2016: Advances in Chronic Kidney Disease
Jéssica Ribeiro Gomes, Rafael A Schmerling, Carolina K Haddad, Douglas J Racy, Robson Ferrigno, Erlon Gil, Pedro Zanuncio, Antônio C Buzaid
Abscopal effect is a rare phenomenon characterized by tumor regression of untreated metastatic lesions after a local therapy (eg, radiotherapy). We studied the probability of abscopal effect with radiotherapy associated with anti-programmed death cell 1 (PD1) therapy after progression on anti-PD1. This study is a retrospective analysis of patients treated with nivolumab or pembrolizumab for melanoma, non-small cell lung cancer (NSCLC) and renal cancer at Antônio Ermírio de Moraes Oncology Center, Brazil. To be eligible for this analysis, patients must have had unequivocal evidence of disease progression on anti-PD1 therapy and subsequent radiotherapy for any tumor site while still receiving anti-PD1...
November 2016: Journal of Immunotherapy
Julie Bonigen, Christine Raynaud-Donzel, José Hureaux, Nora Kramkimel, Astrid Blom, Géraldine Jeudy, Anne-Laure Breton, Thomas Hubiche, Christophe Bedane, Delphine Legoupil, Anne Pham-Ledard, Julie Charles, Maurice Pérol, Emilie Gérard, Patrick Combemale, Daphné Bonnet, Michèle-Léa Sigal, Emmanuel Mahé
Nivolumab (Opdivo(®) ), pembrolizumab (Keytruda(®) ), atezolizumab, and pidilizumabab are anti-PD1 monoclonal antibodies. Nivolumab is licensed in advanced melanoma and second-line therapy of advanced or metastatic non-small cell lung cancer. When activated, the programmed cell death (PD)-1 is implicated in the inhibition of the immune system. Anti-PD1 removes this inhibition and allows the immune system to control tumour cell progression.(1-4) Immune-mediated toxicity of this treatment have been reported, either organ-specific toxicities - i...
October 14, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
Renato Quirino Ramos, João Luiz Bastos, Marco Aurélio Peres
Population-based studies assessing self-reported periodontal questions in low-income countries are lacking, and therefore we aimed to assess the accuracy of self-reported periodontal items in Brazil. One thousand one hundred and forty adults from Florianópolis, Brazil, had their periodontium clinically examined, and responded to the following self-reported items on periodontal conditions: Question (Q)1, Do you have any wobbly teeth?; Q2, Do your gums usually bleed?; and Q3, Has your dentist ever told you that you have gum disease? Periodontitis was defined as: a...
October 10, 2016: Brazilian Oral Research
Duan Bin, Beibei Yang, Ke Zhang, Caiqin Wang, Jin Wang, Jiatai Zhong, Yue Feng, Jun Guo, Yukou Du
In this study, galvanic replacement provides a simple route for the synthesis of PdAg hollow nanoflower structures by using the Ag-seeds as sacrificial templates in the presence of l-ascorbic acid (reductant) and CTAC (capping agent). Transmission electron microscopy (TEM), scanning electron microscopy (SEM), X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), and EDS mapping were used to characterize the as-prepared PdAg hollow nanoflower catalysts, where they were alloyed nanoflower structures with hollow interiors...
October 10, 2016: Chemistry: a European Journal
Weixin Huang, Shiran Zhang, Yu Tang, Yuting Li, Luan Nguyen, Yuanyuan Li, Junjun Shan, Dequan Xiao, Raphael Gagne, Anatoly I Frenkel, Franklin Feng Tao
Direct conversion of methane to chemical feedstocks such as methanol under mild conditions is a challenging but ideal solution for utilization of methane. Pd1 O4 single-sites anchored on the internal surface of micropores of a microporous silicate exhibit high selectivity and activity in transforming CH4 to CH3 OH at 50-95 °C in aqueous phase through partial oxidation of CH4 with H2 O2 . The selectivity for methanol production remains at 86.4 %, while the activity for methanol production at 95 °C is about 2...
October 17, 2016: Angewandte Chemie
Paulina Własiuk, Maciej Putowski, Krzysztof Giannopoulos
The appropriate function of the immune system depends on the effective regulation of the immune response on multiple levels. The key element of an effective immune response to antigenic stimulation is maintaining a homeostasis between activation and inhibitory function of immunocompetent cells and molecules. In pathological conditions such as chronic infections, autoimmune diseases or cancer there are significant alterations, and prevalence of signals of one type over another. Main markers of these dysfunctions are altered expressions of molecules, such as programmed death-1 (PD-1), Human Leukocyte Antigen G (HLA-G), or changed percentages of T regulatory cells (Treg)...
October 4, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
Miwa Sugiura, Yui Ozaki, Fabrice Rappaport, Alain Boussac
Two mutants, D1-H198Q and D1-H198A, have been previously constructed in Thermosynechococcus elongatus with the aim at modifying the redox potential of the P680(•+)/P680 couple by changing the axial ligand of PD1, one the two chlorophylls of the Photosystem II primary electron donor [Sugiura et al., Biochim. Biophys. Acta 1777 (2008) 331-342]. However, after the publication of this work it was pointed out to us by Dr. Eberhard Schlodder (Technische Universität Berlin) that in both mutants the pheophytin band shift which is observed upon the reduction of QA was centered at 544nm instead of 547nm, clearly showing that the D1 protein corresponded to PsbA1 whereas the mutants were supposedly constructed in the psbA3 gene so that the conclusions in our previous paper were wrong...
October 2, 2016: Biochimica et Biophysica Acta
C Baues, R Semrau, U S Gaipl, P J Bröckelmann, J Rosenbrock, A Engert, S Marnitz
BACKGROUND: Patients with classical Hodgkin's lymphoma (cHL) have a good prognosis even in advanced stages. However, combined chemo- and radiotherapy, as the standard of care, is also associated with treatment-related toxicities such as organ damage, secondary neoplasias, infertility, or fatigue and long-term fatigue. Many patients suffer from this burden although their cHL was cured. Therefore, the efficacy of immune checkpoint inhibitors like anti-PD1/PD-L1 antibodies in the treatment of solid cancers and also in HL offers new options...
October 4, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
G Sonpavde, G R Pond, S Mullane, A A Ramirez, N J Vogelzang, A Necchi, T Powles, J Bellmunt
OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) following discontinuation of programmed death-1 (PD-1) or PD-Ligand (L)1 inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration following PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data were collected from institutions including demographics and therapy administered...
October 4, 2016: BJU International
Laurence C Menard, Sium Habte, Waldemar Gonsiorek, Deborah Lee, Dana Banas, Deborah A Holloway, Nataly Manjarrez-Orduno, Mark Cunningham, Dawn Stetsko, Francesca Casano, Selena Kansal, Patricia M Davis, Julie Carman, Clarence K Zhang, Ferva Abidi, Richard Furie, Steven G Nadler, Suzanne J Suchard
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease driven by both innate and adaptive immune cells. African Americans tend to present with more severe disease at an earlier age compared with patients of European ancestry. In order to better understand the immunological differences between African American and European American patients, we analyzed the frequencies of B cell subsets and the expression of B cell activation markers from a total of 68 SLE patients and 69 normal healthy volunteers...
June 16, 2016: JCI Insight
Claudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, Patrizia Agati, Claudio Tripodo, Fabio Fuligni, Maria Teresa Sista, Stefano Fanti, Alberto Biggi, Umberto Vitolo, Luigi Rigacci, Francesco Merli, Caterina Patti, Alessandra Romano, Alessandro Levis, Livio Trentin, Caterina Stelitano, Anna Borra, Pier Paolo Piccaluga, Stephen Hamilton-Dutoit, Peter Kamper, Jan Maciej Zaucha, Bogdan Małkowski, Waldemar Kulikowski, Joanna Tajer, Edyta Subocz, Justyna Rybka, Christian Steidl, Alessandro Broccoli, Lisa Argnani, Randy D Gascoyne, Francesco d'Amore, Pier Luigi Zinzani, Stefano A Pileri
BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease. METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to Dec 31, 2012...
October 2016: Lancet Haematology
A L Ridler, R A Corner-Thomas, P R Kenyon, K J Griffiths
AIMS: To investigate associations between changes in liveweight and fetal loss in ewe lambs and to determine whether fetal loss was associated with concentrations of progesterone in early and mid-gestation. METHODS: Ewe lambs on two commercial sheep farms (Flock A; n=504 and Flock B; n=460) in the southern North Island of New Zealand were weighed, and body condition score was assessed, prior to breeding and throughout pregnancy. Pregnancy diagnosis was undertaken approximately 56 (PD1), 80 (PD2) and 110 (PD3) days after the start of breeding and fetal loss determined...
October 2, 2016: New Zealand Veterinary Journal
Huachun Lan, Ran Mao, Yating Tong, Yanzhen Liu, Huijuan Liu, Xiaoqiang An, Ruiping Liu
In this work, the electroreductive removal of bromate by a Pd1-In4/Al2O3 catalyst in a three-dimensional electrochemical reactor was investigated. A total of 96.4% of bromate could be efficiently reduced and completely converted into bromide within 30 min under optimized conditions. On the basis of the characterization results and kinetics analysis, a synergistic effect of Pd and In was observed, and Pd1-In4/Al2O3 had the highest reaction rate constant of 0.1275 min(-1) (vs 0.0413, 0.0328, and 0.0253 min(-1) for In/Al2O3, Pd/Al2O3, and Al2O3)...
October 12, 2016: Environmental Science & Technology
Eduardo Castañón
Anti-PD1 antibodies have led to a therapeutic shift in cancer treatment. Although classically described as "well-tolerated", these drugs can lead to severe immune related adverse events. Using CT scan imaging, Nishino and colleagues describe different radiological patterns and their possible relation to severity of several cases of anti-PD1 induced pneumonitis.
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Pedro Aguiar, Gilberto Lopes, Ilka Santoro, Hakaru Tadokoro, Carmelia Barreto, Ramon De Mello
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Richard J Gralla, David Spigel, Bryan Bennett, Fiona Taylor, John R Penrod, Michael Derosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Roy S Herbst, Paul Baas, Jose L Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary Jo Fidler, Veerle Surmont, Gilberto De Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B Garon
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Paola X De La Iglesia, Liliana Dalurzo, Maria J Labanca
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"